Concepedia

Publication | Open Access

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

DOIFull Paper Access

94

Citations

27

References

2018

Year

Andrew B. Lassman, Martin J. van den Bent, Hui Gan, David A. Reardon, Priya Kumthekar, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Burt Nabors, Kyriakos P. Papadopoulos,
Neuro-Oncology

Abstract

Depatux-m + TMZ displayed an AE profile similar to what was described previously. Antitumor activity in this TMZ-refractory population was encouraging. Continued study of depatux-m in patients with EGFR-amplified, newly diagnosed, or recurrent GBM is ongoing in 2 global, randomized trials (NCT02573324, NCT02343406).

References

YearCitations

Page 1